Carasent AB

Carasent AB

26.95
SEK
-1.50
(-5.27%)
0.34EPS
67.44P/E
1.52BMarket Cap
Feb 04Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
13.95
15.7
13.58
10.56
- -
0.62
1.33
1.45
2.15
2.62
3.15
3.7
4.97
5.19
Basic EPS, GAAP
0.26
-4.23
2.7
7.74
1
-0.18
0.09
-0.78
- -
0.42
-0.6
-0.57
0.5
0.34
Free Cash Flow per Basic Share
1.43
1.2
-1.58
-2.03
2.49
-0.06
0.04
0.05
-0.09
-0.78
-0.95
-0.07
-0.01
0.89
Dividend per Share
- -
- -
3.99
7.29
- -
- -
- -
- -
- -
- -
1.67
- -
- -
- -
Book Value per Share
7.18
4.41
3.21
2.67
3
2.38
2.52
6.71
15.7
16.3
13.04
12.01
11.8
11.85
Tangible Book Value per Share
-0.25
-2.08
-0.79
2.67
3
-0.22
-0.25
2.55
10.68
8.37
4.61
2.42
1.71
-0.38
Basic Weighted Avg Shares
20
20
20
20
20
41
41
45
67
79
78
72
69
70
Sales/Revenue/Turnover
284
320
276
215
- -
25
54
65
145
208
245
268
344
365
Operating Margin (%)
4.93
-4.27
-17.3
-0.8
- -
-28.16
9.35
4.86
7.03
-0.7
-15.39
-17.95
2.74
0.81
Depreciation Expense
30
36
22
14
- -
4
8
12
25
36
51
59
64
66
Net Income, GAAP
5
-86
55
158
20
-7
4
-35
- -
33
-47
-41
35
24
Effective Tax Rate (%)
17.44
- -
4.03
- -
- -
- -
23.36
- -
103.96
7.98
- -
- -
- -
8.74
Profit Margin (%)
1.87
-26.93
19.91
73.25
- -
-29.35
6.7
-54.03
-0.11
15.96
-19.04
-15.35
10.08
6.51
Working Capital
-12
-93
-1
11
61
- -
-2
181
844
677
330
194
106
-29
LT Debt
52
25
47
- -
- -
2
17
12
11
30
37
29
19
15
Total Equity
146
90
65
54
61
97
102
369
1,235
1,298
943
868
808
792
Return on Invested Capital (%)
4.98
- -
39.22
- -
-10.01
- -
3.44
- -
-0.05
-0.1
- -
- -
- -
0.31
Return on Capital (%)
4.98
- -
39.1
- -
35.27
- -
3.45
- -
-0.02
2.66
- -
- -
- -
2.73
Return on Common Equity (%)
3.51
-73.12
71.01
263.11
35.27
-9.43
3.65
-14.89
-0.02
2.62
-4.17
-4.54
4.14
2.83

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
13
13
14
LT Borrowings
- -
- -
- -
LT Finance Leases
19
16
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
67
67
Market Capitalization
1,879
1,534
1,524

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
218
196
126
Cash, Cash Equivalents & STI
138
130
51
Accounts Receivable, Net
55
36
43
Inventories
- -
- -
- -
Total Current Liabilities
112
124
155
Payables & Accruals
- -
- -
- -
ST Debt
13
13
14
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
51.75%
39.41%
-6.95%
Free Cash Flow
-3.46%
80.77%
-90.5%
Net Income, GAAP
-2,315.71%
-4,380.77%
-184.36%
Sales/Revenue/Turnover
- -
44.33%
28.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
65
65
62
77
268
2025
85
83
- -
94
344
2026
90
98
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.08
-0.03
-0.33
-0.57
2025
-0.04
-0.08
- -
0.42
0.5
2026
0.04
-0.04
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Daniel Öhman
Full Time Employees
196
Sector
Technology services
Industry
Packaged software
Address
Nellickevägen 20 Gothenburg VG Sweden 412 63
IPO Date
Dec 21, 2007
Business
Carasent AB (publ) Carasent AB (publ) is a Sweden-based technology company that develops and provides cloud-based electronic health record (EHR) systems and platform services for the healthcare, rehabilitation, and occupational health sectors; its core EHR software portfolio includes Webdoc, Webdoc X, Metodika, Ad Curis, Ad Opus, and Data-AL, while platform services encompass Medrave for business intelligence, patient communication solutions such as Vårdrummet and Ad Voca, and occupational health tools like HPI Plustoo. The company serves private clinics, public regions, addiction treatment centers, and occupational health providers primarily in the Nordics—including Sweden, Norway, and through offices in Gothenburg (headquarters), Stockholm, Oslo, and Dale—and expanded into Germany with operations in Neu-Ulm; founded in 1997, Carasent AB (publ) operates a decentralized structure across subsidiaries to maintain market proximity and expertise in specialized healthcare segments. Recent developments include the October 2024 acquisition of Data-AL GmbH for an initial EUR 8 million to strengthen its German presence with over 1,000 private clinic customers, a December 2024 cross-border merger with Carasent ASA to relist on Nasdaq Stockholm from the Oslo Stock Exchange, major customer contracts such as Metodika with Volvat Medicinska Senter and Ad Curis with Frelsesarmeen generating SEK 16-18 million in annual recurring revenue, a February 2024 divestiture of the Confrere brand, ISO 14001 sustainability certification in September 2024, and product advancements like e-referral features in Webdoc alongside organizational restructuring in Ad Opus to enhance efficiency.